Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Identifieur interne : 004025 ( Ncbi/Merge ); précédent : 004024; suivant : 004026Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Auteurs : Stephen J. Luen [Australie] ; Roberto Salgado [Belgique] ; Stephen Fox [Australie] ; Peter Savas [Australie] ; Jennifer Eng-Wong [États-Unis] ; Emma Clark [Royaume-Uni] ; Astrid Kiermaier [Suisse] ; Sandra M. Swain [États-Unis] ; Jose Baselga [États-Unis] ; Stefan Michiels [France] ; Sherene Loi [Australie]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Femelle, Humains, Invasion tumorale, Jeune adulte, Lymphocytes TIL (anatomopathologie), Lymphocytes TIL (immunologie), Marqueurs biologiques tumoraux (métabolisme), Métastase lymphatique, Méthode en double aveugle, Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récepteur ErbB-2 (métabolisme), Stade de la tumeur, Sujet âgé, Taux de survie, Taxoïdes (administration et posologie), Trastuzumab (administration et posologie), Tumeurs du sein (anatomopathologie), Tumeurs du sein (immunologie), Tumeurs du sein (métabolisme), Tumeurs du sein (traitement médicamenteux), Études de suivi, Études rétrospectives.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Taxoïdes, Trastuzumab.
- anatomopathologie : Lymphocytes TIL, Tumeurs du sein.
- immunologie : Lymphocytes TIL, Tumeurs du sein.
- métabolisme : Marqueurs biologiques tumoraux, Récepteur ErbB-2, Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Invasion tumorale, Jeune adulte, Métastase lymphatique, Méthode en double aveugle, Pronostic, Stade de la tumeur, Sujet âgé, Taux de survie, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Tumor (metabolism), Breast Neoplasms (drug therapy), Breast Neoplasms (immunology), Breast Neoplasms (metabolism), Breast Neoplasms (pathology), Double-Blind Method, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Lymphocytes, Tumor-Infiltrating (immunology), Lymphocytes, Tumor-Infiltrating (pathology), Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Receptor, ErbB-2 (metabolism), Retrospective Studies, Survival Rate, Taxoids (administration & dosage), Trastuzumab (administration & dosage), Young Adult.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Taxoids, Trastuzumab.
- chemical , metabolism : Biomarkers, Tumor, Receptor, ErbB-2.
- drug therapy : Breast Neoplasms.
- immunology : Breast Neoplasms, Lymphocytes, Tumor-Infiltrating.
- metabolism : Breast Neoplasms.
- pathology : Breast Neoplasms, Lymphocytes, Tumor-Infiltrating.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adolescent, Adult, Aged, Double-Blind Method, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Young Adult.
Abstract
High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel.
DOI: 10.1016/S1470-2045(16)30631-3
PubMed: 27964843
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001339
- to stream PubMed, to step Curation: 001317
- to stream PubMed, to step Checkpoint: 001317
Links to Exploration step
pubmed:27964843Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.</title><author><name sortKey="Luen, Stephen J" sort="Luen, Stephen J" uniqKey="Luen S" first="Stephen J" last="Luen">Stephen J. Luen</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Fox, Stephen" sort="Fox, Stephen" uniqKey="Fox S" first="Stephen" last="Fox">Stephen Fox</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Savas, Peter" sort="Savas, Peter" uniqKey="Savas P" first="Peter" last="Savas">Peter Savas</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Eng Wong, Jennifer" sort="Eng Wong, Jennifer" uniqKey="Eng Wong J" first="Jennifer" last="Eng-Wong">Jennifer Eng-Wong</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Clark, Emma" sort="Clark, Emma" uniqKey="Clark E" first="Emma" last="Clark">Emma Clark</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products, Welwyn, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products, Welwyn</wicri:regionArea><wicri:noRegion>Welwyn</wicri:noRegion></affiliation></author><author><name sortKey="Kiermaier, Astrid" sort="Kiermaier, Astrid" uniqKey="Kiermaier A" first="Astrid" last="Kiermaier">Astrid Kiermaier</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Biomarker Development, Roche, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Oncology Biomarker Development, Roche, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Swain, Sandra M" sort="Swain, Sandra M" uniqKey="Swain S" first="Sandra M" last="Swain">Sandra M. Swain</name><affiliation wicri:level="2"><nlm:affiliation>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="Jose" last="Baselga">Jose Baselga</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="4"><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27964843</idno><idno type="pmid">27964843</idno><idno type="doi">10.1016/S1470-2045(16)30631-3</idno><idno type="wicri:Area/PubMed/Corpus">001339</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001339</idno><idno type="wicri:Area/PubMed/Curation">001317</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001317</idno><idno type="wicri:Area/PubMed/Checkpoint">001317</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001317</idno><idno type="wicri:Area/Ncbi/Merge">004025</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.</title><author><name sortKey="Luen, Stephen J" sort="Luen, Stephen J" uniqKey="Luen S" first="Stephen J" last="Luen">Stephen J. Luen</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Fox, Stephen" sort="Fox, Stephen" uniqKey="Fox S" first="Stephen" last="Fox">Stephen Fox</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Savas, Peter" sort="Savas, Peter" uniqKey="Savas P" first="Peter" last="Savas">Peter Savas</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Eng Wong, Jennifer" sort="Eng Wong, Jennifer" uniqKey="Eng Wong J" first="Jennifer" last="Eng-Wong">Jennifer Eng-Wong</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Clark, Emma" sort="Clark, Emma" uniqKey="Clark E" first="Emma" last="Clark">Emma Clark</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products, Welwyn, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products, Welwyn</wicri:regionArea><wicri:noRegion>Welwyn</wicri:noRegion></affiliation></author><author><name sortKey="Kiermaier, Astrid" sort="Kiermaier, Astrid" uniqKey="Kiermaier A" first="Astrid" last="Kiermaier">Astrid Kiermaier</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Biomarker Development, Roche, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Oncology Biomarker Development, Roche, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Swain, Sandra M" sort="Swain, Sandra M" uniqKey="Swain S" first="Sandra M" last="Swain">Sandra M. Swain</name><affiliation wicri:level="2"><nlm:affiliation>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="Jose" last="Baselga">Jose Baselga</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="4"><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers, Tumor (metabolism)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (immunology)</term><term>Breast Neoplasms (metabolism)</term><term>Breast Neoplasms (pathology)</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Lymphocytes, Tumor-Infiltrating (immunology)</term><term>Lymphocytes, Tumor-Infiltrating (pathology)</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Receptor, ErbB-2 (metabolism)</term><term>Retrospective Studies</term><term>Survival Rate</term><term>Taxoids (administration & dosage)</term><term>Trastuzumab (administration & dosage)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Invasion tumorale</term><term>Jeune adulte</term><term>Lymphocytes TIL (anatomopathologie)</term><term>Lymphocytes TIL (immunologie)</term><term>Marqueurs biologiques tumoraux (métabolisme)</term><term>Métastase lymphatique</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Récepteur ErbB-2 (métabolisme)</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Taxoïdes (administration et posologie)</term><term>Trastuzumab (administration et posologie)</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (immunologie)</term><term>Tumeurs du sein (métabolisme)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Taxoids</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers, Tumor</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Taxoïdes</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lymphocytes TIL</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes TIL</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Breast Neoplasms</term><term>Lymphocytes, Tumor-Infiltrating</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Récepteur ErbB-2</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term><term>Lymphocytes, Tumor-Infiltrating</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Retrospective Studies</term><term>Survival Rate</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Invasion tumorale</term><term>Jeune adulte</term><term>Métastase lymphatique</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27964843</PMID><DateCreated><Year>2016</Year><Month>12</Month><Day>14</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol.</ISOAbbreviation></Journal><ArticleTitle>Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.</ArticleTitle><Pagination><MedlinePgn>52-62</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(16)30631-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(16)30631-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">CLEOPATRA was a randomised phase 3 study comparing the addition of either pertuzumab or placebo to first-line therapy with trastuzumab and docetaxel for patients with locally recurrent, unresectable, or metastatic HER2-positive breast cancer. We assessed the quantity of stromal TILs in prospectively collected tumour samples and investigated their association with progression-free survival, overall survival, clinicopathological characteristics, and pertuzumab treatment. We estimated hazard ratios (HR) and 95% CIs with multivariate Cox regression models fitting stromal TILs as a continuous variable (per 10% increment). The CLEOPATRA trial is registered with ClinicalTrials.gov, number NCT00567190.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Tumour samples from 678 (84%) of 808 participants were evaluable for TILs, including 519 (77%) archival samples, 155 (23%) freshly obtained samples (collected 45 days or fewer before randomisation), and four samples of unknown archival status. Median follow-up was 50 months (IQR 41-54) for progression-free survival and 51 months (IQR 46-57) for overall survival. 519 progression-free survival events occurred and 358 patients died. The median TIL value was 10% (IQR 5-30). Freshly obtained tumour samples had significantly lower TIL values than did archival samples (10·00% [95% CI 5·00-20·00] vs 15·00% [5·00-35·00]; p=0·00036). We detected no significant association between TIL values and progression-free survival (adjusted HR 0·95, 95% CI 0·90-1·00, p=0·063). However, for overall survival, each 10% increase in stromal TILs was significantly associated with longer overall survival (adjusted HR 0·89, 95% CI 0·83-0·96, p=0·0014). The treatment effect of pertuzumab did not differ significantly by stromal TIL value for either progression-free survival (pinteraction=0·23) or overall survival (pinteraction=0·21).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">In patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significantly associated with improved overall survival, suggesting that the effect of antitumour immunity extends to the advanced setting. Future clinical studies in this cancer subtype should consider TILs as a stratification factor and investigate whether therapies that can augment immunity could potentially further improve survival.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundation.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luen</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salgado</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savas</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eng-Wong</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Roche Products, Welwyn, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiermaier</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oncology Biomarker Development, Roche, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swain</LastName><ForeName>Sandra M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baselga</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loi</LastName><ForeName>Sherene</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00567190</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043823">Taxoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>15H5577CQD</RegistryNumber><NameOfSubstance UI="C067311">docetaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>K16AIQ8CTM</RegistryNumber><NameOfSubstance UI="C485206">pertuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Oct 22;373(17):1627-39</RefSource><PMID Version="1">26412456</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2015 Feb;26(2):259-71</RefSource><PMID Version="1">25214542</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Oncol. 2014 Nov;26(6):562-7</RefSource><PMID Version="1">25188474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7</RefSource><PMID Version="1">21482773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2010 Aug 9;18(2):160-70</RefSource><PMID Version="1">20708157</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2015 Oct;21(10):1128-38</RefSource><PMID Version="1">26444637</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1987 Jan 9;235(4785):177-82</RefSource><PMID Version="1">3798106</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Sep 20;32(27):2935-7</RefSource><PMID Version="1">25071115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2009 Dec 15;69(24):9330-6</RefSource><PMID Version="1">19934333</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52</RefSource><PMID Version="1">19815849</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Oncol. 2015 Jul;1(4):448-54</RefSource><PMID Version="1">26181252</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Nov 5;373(19):1803-13</RefSource><PMID Version="1">26406148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hum Genet. 2005;50(5):264-6</RefSource><PMID Version="1">15883854</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jan 8;372(2):134-41</RefSource><PMID Version="1">25564897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2016 Jun;157(3):575-86</RefSource><PMID Version="1">27255533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2004 Apr;5(4):317-28</RefSource><PMID Version="1">15093539</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2016 Jun;27(6):1029-34</RefSource><PMID Version="1">26961151</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2002 Aug;2(2):127-37</RefSource><PMID Version="1">12204533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Discov. 2017 Jan;7(1):72-85</RefSource><PMID Version="1">27694385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 2016 Oct;29(10):1155-64</RefSource><PMID Version="1">27363491</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jan 1;28(1):105-13</RefSource><PMID Version="1">19917869</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 May 21;372(21):2018-28</RefSource><PMID Version="1">25891174</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Aug;25(8):1544-50</RefSource><PMID Version="1">24608200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Feb;24(2):273-82</RefSource><PMID Version="1">22910839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Mar 1;31(7):860-7</RefSource><PMID Version="1">23341518</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Sep 20;32(27):2959-66</RefSource><PMID Version="1">25071121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Nov 20;32(33):3753-61</RefSource><PMID Version="1">25332247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Immunol. 2014 Apr;27:16-25</RefSource><PMID Version="1">24531241</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Mar 20;33(9):983-91</RefSource><PMID Version="1">25534375</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Feb 19;372(8):724-34</RefSource><PMID Version="1">25693012</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>01</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27964843</ArticleId><ArticleId IdType="pii">S1470-2045(16)30631-3</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(16)30631-3</ArticleId><ArticleId IdType="pmc">PMC5477653</ArticleId><ArticleId IdType="mid">NIHMS861211</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>District de Columbia</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Bruxelles</li><li>Melbourne</li><li>Orsay</li></settlement><orgName><li>Université Paris-Sud</li><li>Université de Melbourne</li><li>Université libre de Bruxelles</li></orgName></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Luen, Stephen J" sort="Luen, Stephen J" uniqKey="Luen S" first="Stephen J" last="Luen">Stephen J. Luen</name></region><name sortKey="Fox, Stephen" sort="Fox, Stephen" uniqKey="Fox S" first="Stephen" last="Fox">Stephen Fox</name><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><name sortKey="Savas, Peter" sort="Savas, Peter" uniqKey="Savas P" first="Peter" last="Savas">Peter Savas</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name></region></country><country name="États-Unis"><region name="Californie"><name sortKey="Eng Wong, Jennifer" sort="Eng Wong, Jennifer" uniqKey="Eng Wong J" first="Jennifer" last="Eng-Wong">Jennifer Eng-Wong</name></region><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="Jose" last="Baselga">Jose Baselga</name><name sortKey="Swain, Sandra M" sort="Swain, Sandra M" uniqKey="Swain S" first="Sandra M" last="Swain">Sandra M. Swain</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Clark, Emma" sort="Clark, Emma" uniqKey="Clark E" first="Emma" last="Clark">Emma Clark</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Kiermaier, Astrid" sort="Kiermaier, Astrid" uniqKey="Kiermaier A" first="Astrid" last="Kiermaier">Astrid Kiermaier</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004025 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004025 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27964843
|texte= Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27964843" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |